Navigation Links
Talecris Biotherapeutics Receives FDA Approval for PROLASTIN(R)-C
Date:10/19/2009

ASTIN and PROLASTIN-C are made from human plasma. Products made from human plasma may contain infectious agents, such as viruses and, theoretically, the Creutzfeldt-Jakob (CJD) agent that can cause disease, and cannot be totally eliminated. There is also the possibility that unknown infectious agents may be present in such products. Individuals with selective IgA deficiencies who have the known antibody against IgA (anti-IgA antibody) should not receive PROLASTIN or PROLASTIN-C, since these patients may experience severe reactions, including anaphylaxis, to IgA which may be present. For additional information on PROLASTIN, please see full prescribing information at www.PROLASTIN.com.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

About Alpha1-Antitrypsin Deficiency

Alpha1-antitrypsin deficiency, also known as AAT deficiency or Alpha-1, is an inherited disorder that causes significant reduction in the naturally occurring protein AAT. It is most common in the Caucasian population of northern Europe and North America. AAT deficiency is also the most common cause of genetic liver disease in children, and genetic emphysema (shortness of breath) in adults. Individuals suffering from AAT deficiency often develop severe obstructive pulmonary disease (COPD) causing disability and premature death. AAT deficiency is estimated to affect 200,000 people in North America and Europe.

About Talecris Biotherapeutics: Inspiration. Dedication. Innovation.

Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, neurology an
'/>"/>

SOURCE Talecris Biotherapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
2. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
3. Juvaris BioTherapeutics Announces Cooperative Research and Development Agreement With The Centers for Disease Control and Prevention
4. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
5. Oxygen Biotherapeutics, Inc. Receives Letter From FDA Outlining Path Forward to Resume Oxycyte Clinical Trials in TBI in U.S.A.
6. Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies
7. Oxygen Biotherapeutics, Inc. Submits Milestone Achievement Notice to Vatea Fund
8. Oxygen Biotherapeutics, Inc. Receives Phase II Trial Approval in Israel
9. Oxygen Biotherapeutics, Inc. to Webcast Shareholder Meeting
10. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
11. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014  KIYATEC announced today ... Small Business Innovation Research (SBIR) Phase II Contract ... the 27 institutes and centers that comprise the ... of the two year award, KIYATEC will expand ... issues at the forefront of cancer therapy strategies: ...
(Date:9/18/2014)... LONDON , September 18, 2014 ... their audience, has updated the incredibly successful Serialisation Countdown ... The interactive PDF, available at pharmaserialisation.com shows ... in which they will be coming into force. ... no longer a matter of "if", but "when" they ...
(Date:9/18/2014)... ARBOR, Mich. , Sept. 18, 2014  A ... Research will allow the University of Michigan to establish ... The Glenn Center for Aging Research at ... evidence that drugs can slow the effects of aging ... unlock mechanisms of aging that can help develop medications ...
Breaking Medicine Technology:National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 2National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 3Pharma IQ Displays Worldwide Serialisation Deadlines in their 2014 - 2018 Countdown Calendar 2$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 2$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 3
(Date:9/18/2014)... living in disadvantaged neighborhoods have worse musculoskeletal pain ... motor vehicle collision than individuals from higher socioeconomic ... such as age, sex, income, education, and employment ... multi-site research study led by Samuel McLean, MD, ... at the University of North Carolina School of ...
(Date:9/18/2014)... September 18, 2014 It is almost time ... or walk for healthier and happier kids. The South ... in the 4th Annual Miami Children’s Hospital 5K Run/Walk. ... http://www.hyundaihopeonwheels.org , The 5K will take place on ... be outside of Coral Gables City Hall located at 405 ...
(Date:9/18/2014)... Good Neighbor Pharmacy, a national independent ... Pharmacy University, an online central resource for network ... empower pharmacy owners and their staff in today’s ... evolve, Good Neighbor Pharmacy is a partner to ... to help their businesses thrive,” said Scott Robinson, ...
(Date:9/18/2014)... parents eat more vegetables and drink less sugar, according ... Columbia. But it,s still not enough, the study goes ... when it comes to eating healthier at school , ... of socioeconomic status, may inform a child,s diet. , ... some post-secondary education were 85 per cent more likely ...
(Date:9/18/2014)... Relias Learning, the leader in SaaS-based training and ... announced it has been named to the Inc. 5000 list ... , In the three-year period from 2010 to 2013, Relias ... on the Inc. 5000 list to 1,025 from the company’s ... we serve continue to grow, and the need for quality ...
Breaking Medicine News(10 mins):Health News:Living in a disadvantaged neighborhood worsens musculoskeletal pain outcomes after trauma 2Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 2Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 3Health News:Good Neighbor Pharmacy University Keeps Pharmacists Ahead of the Curve 2Health News:Kids eat better if their parents went to college 2Health News:Relias Learning Named to Inc. 5000 List for Second Consecutive Year 2
... (Nov. 3, 2011) Because the incidence of malignant ... the U.S., researchers at Moffitt Cancer Center in Tampa, ... Carolina University and the University of Arizona are working ... malignant melanoma diagnosis and therapy. A tool of great ...
... Reinberg HealthDay Reporter , WEDNESDAY, Nov. 2 ... therapy prolongs survival among men whose cancer has spread ... These men have what is called high-risk, or locally ... to 25 percent fall into this category. In the ...
... 3 (HealthDay News) -- The first artificial heart valve ... approved by the U.S. Food and Drug Administration. ... an aortic heart valve damaged by senile aortic valve ... deposits that cause the valve to narrow. One ...
... Severe early childhood caries can destroy most of a ... populations, including American Indians and Alaskan natives. Although the ... early childhood caries has been known for almost a ... are responsible for the disease has remained elusive. ...
... (HealthDay News) -- Allergy shots are time-tested treatments ... relief to allergy sufferers within weeks instead of months, ... currently given under the skin (subcutaneously), new methods of ... week,s annual scientific meeting of the American College of ...
... , WEDNESDAY, Nov. 2 (HealthDay News) -- A compound currently ... hemophilia patients also seems to be effective in preventing bleeds ... in the Nov. 3 edition of the New England ... last long, the results do raise the possibility that, over ...
Cached Medicine News:Health News:Researchers help in search for new ways to image, therapeutically target melanoma 2Health News:Radiation Plus Hormone Therapy Extends Life in High-Risk Prostate Cancer 2Health News:Radiation Plus Hormone Therapy Extends Life in High-Risk Prostate Cancer 3Health News:FDA OKs Heart Valve That Does Not Require Open-Heart Surgery 2Health News:FDA OKs Heart Valve That Does Not Require Open-Heart Surgery 3Health News:NYUCD awarded $2.2 million NIH grant to decode genome of caries-causing bacteria 2Health News:NYUCD awarded $2.2 million NIH grant to decode genome of caries-causing bacteria 3Health News:Improved Allergy Shots Might Be on Horizon 2Health News:Using Drug for Prevention Might Help in Hard-to-Treat Hemophilia 2Health News:Using Drug for Prevention Might Help in Hard-to-Treat Hemophilia 3
... offer the physician a new approach to supportive ... The weight simply uses gravity to gently close ... or when the eyelid muscle is relaxed. ... variety of skin tone colors to match a ...
... Heidelberg Multi Color (HMC) ... a microprocessor-controlled precision assessment ... the red/green range (Rayleigh ... (Moreland equation) with integrated ...
... VersaSuite practice management software is ... the business and clinical aspects of ... solution offers support for the financial, ... the eye care professional. Designed as ...
... in our country to provide greater and ... recent government regulations require it. The Access ... your wheelchair-bound patients easy and comfortable access ... to leave their wheelchair. , ,The Access ...
Medicine Products: